Seattle, Wash. – May 6, 2014 – CMC Biologics, a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics’ product candidates.
“We look forward to working with MacroGenics to further develop and advance this immuno-oncology program,” said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics. “This contract highlights CMC Biologics’ focus on working with our customers as partners and our capabilities in the development and clinical manufacturing of monoclonal antibodies.”
“We are impressed with CMC Biologics’ experience and technical competency in biopharmaceutical development and cGMP manufacturing,” said MacroGenics President and Chief Executive Officer, Scott Koenig, MD, PhD. “Choosing a contract manufacturing partner with quality facilities that is able to provide flexible solutions and meet our clinical timelines is critical to realizing the potential of life-saving medicines.”
About CMC Biologics
CMC Biologics is leading the industry among CMO’s in reliability, technical excellence, and quality – Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and commercial production. The Company’s wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics’ proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. More detailed information can be found at www.cmcbiologics.com.
Stacie D. Byars CMC Biologics Global Marketing email@example.com +1 (206) 660-2588